InfuSystem
InfuSystem's revenue rose 6.4% to $143 million in fiscal 2025. Its operating margin was 8.3%, up from 5.1% a year earlier. Free cash flow was $24 million, up 23.1%. It paid out $10 million in dividends and buybacks, 41% of free cash flow. The diluted share count fell 2.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What InfuSystem does
InfuSystem provides equipment and services that let patients continue treatments at home after leaving a clinic. Its customers are makers of durable medical equipment and health care providers such as hospitals, oncology practices and ambulatory surgery centers. It is based in Rochester Hills, Michigan, and works from seven locations in the United States and Canada.
It has two platforms. Patient Services is its main one. It supplies the equipment and treatment supplies, handles orders and delivery, provides nursing support around the clock, bills insurers and keeps the equipment inspected and repaired. Its experience is mainly in oncology, and it says it wants to extend the model to other types of equipment. Device Solutions covers equipment rentals and sales, supply sales and equipment support services for providers.
Much of its revenue comes from insurers and other third-party payers that pay for the care, so it relies on estimates of what it will collect from them.
Its biggest risks, as it describes them
- Changes to the health care reimbursement system could hurt its business.
- It depends on estimates of how much it will collect from insurers and other payers.
- Losing a relationship with one or more payers, or having too much revenue from a few payers.
- New studies could show that treatments that don't use its pumps work as well as ones that do.
Income statement
From fiscal 2019 to 2025, earnings per share grew 28.1% a year and net income 29.5% a year, as new shares raised the share count by 1% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 0 | 0 | 0 | 3 |
| Debt incl. finance leases | 33 | 33 | 29 | 24 | 20 |
| Net debt (negative means net cash) | 33 | 33 | 29 | 23 | 16 |
| Net debt to EBITDA | 1.9x | 2.2x | 1.7x | 1.2x | 0.7x |
| Debt to equity | 0.7x | 0.7x | 0.6x | 0.4x | 0.3x |
| Interest coverage | 2.0x | 1.2x | 1.9x | 3.9x | 9.2x |
| Current ratio | 1.7x | 1.7x | 1.9x | 1.8x | 1.8x |
| Quick ratio | 1.4x | 1.4x | 1.5x | 1.4x | 1.5x |
Cash flow
Projections
Project InfuSystem's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What InfuSystem says to expect
- Full year 2026: net revenue and adjusted EBITDA margin
InfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma net revenue growth is estimated to be between 6% and 8% for 2026. We also are continuing to forecast Adjusted EBITDA margin (non-GAAP) to be in the low-to-mid 20% range.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $150,396 of InfuSystem shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 11, 2026 | Carrie LachancePresident and CEO, Director | Bought | 1,000 | $8.46 | $8,460 | Form 4 |
| May 8, 2026 | Barry G SteeleExecutive VP and CFO | Bought | 7,000 | $8.71 | $60,970 | Form 4 |
| May 8, 2026 | Paul Andrew GendronDirector | Bought | 5,000 | $8.88 | $44,400 | Form 4 |
| May 8, 2026 | Carrie LachancePresident and CEO, Director | Bought | 2,000 | $8.83 | $17,660 | Form 4 |
| Mar 2, 2026 | Barry G SteeleExecutive VP and CFO | Bought | 2,064 | $9.16 | $18,906 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 7 of 9 | 8 of 9 |
| Rule of 40 | 22.6% | 21.6% | 23.0% |
| Altman Z'' | 0.45 | 0.87 | 1.27 |
| Accruals ratio | −10.2% | −17.5% | −17.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 7 of 9 | 7 of 9 | 8 of 9 |
Compare
Put InfuSystem side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| InfuSystem | FY25 | 6.4% | 8.3% | 16.6% | 9.6% | 0.7x | 8 | |
| Neuronetics | FY25 | 99.2% | −21.1% | −14.2% | −37.5% | — | 4 | Compare |
| Xtant Medical | FY25 | 14.2% | 5.4% | 7.6% | 10.0% | −0.5x | 8 | Compare |
| Outset Medical | FY25 | 5.1% | −55.8% | −39.4% | −88.0% | — | 6 | Compare |
| OraSure Technologies | FY25 | −38.1% | −62.6% | −46.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 70 | 71 | 67 | 81 | 97 | 102 | 110 | 126 | 135 | 143 |
| Revenue growth | −0.1% | 0.8% | −5.5% | 20.8% | 20.1% | 5.1% | 7.4% | 14.4% | 7.2% | 6.4% |
| Gross profit | 45 | 43 | 40 | 47 | 59 | 58 | 61 | 63 | 70 | 80 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 1 | −4 | 0 | 4 | 9 | 3 | 2 | 4 | 7 | 12 |
| Net income | −0 | −21 | −1 | 1 | 17 | 1 | 0 | 1 | 2 | 7 |
| Diluted EPS (US$) | −0.01 | −0.91 | −0.05 | 0.07 | 0.80 | 0.06 | 0.00 | 0.04 | 0.11 | 0.31 |
| Diluted shares (millions) | 23 | 23 | 21 | 21 | 22 | 22 | 22 | 22 | 22 | 21 |
| Cash flow | ||||||||||
| Cash from operations | 8 | 8 | 11 | 14 | 20 | 18 | 18 | 11 | 20 | 24 |
| Capital expenditure | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 1 | 1 | 1 |
| Free cash flow | 8 | 8 | 11 | 11 | 19 | 17 | 17 | 10 | 19 | 24 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 10 | 0 | 0 | 1 | 6 | 0 | 1 | 10 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 1 |
| Stock-based compensation | 0 | 1 | 1 | 1 | 3 | 6 | 4 | 4 | 4 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 3 | 4 | 4 | 3 | 10 | 0 | 0 | 0 | 0 | 3 |
| Debt incl. finance leases | 32 | 28 | 34 | 38 | 39 | 33 | 33 | 29 | 24 | 20 |
| Total assets | 96 | 69 | 64 | 79 | 97 | 98 | 99 | 103 | 104 | 101 |
| Total liabilities | 46 | 38 | 44 | 57 | 56 | 49 | 51 | 51 | 46 | 43 |
| Shareholders' equity | 51 | 31 | 20 | 22 | 41 | 48 | 48 | 52 | 58 | 57 |
| Margins and ratios | ||||||||||
| Gross margin | 63.5% | 61.0% | 58.9% | 57.8% | 60.3% | 57.2% | 55.1% | 50.2% | 52.2% | 56.0% |
| Operating margin | 1.4% | −5.4% | 0.6% | 4.3% | 9.1% | 2.8% | 1.5% | 3.2% | 5.1% | 8.3% |
| Net margin | −0.3% | −29.1% | −1.6% | 1.7% | 17.8% | 1.4% | 0.0% | 0.7% | 1.7% | 4.6% |
| Free cash flow margin | 11.0% | 10.7% | 16.6% | 13.5% | 19.7% | 16.9% | 15.0% | 8.1% | 14.4% | 16.6% |
| Rule of 40 (growth + FCF margin) | 10.9% | 11.5% | 11.0% | 34.3% | 39.8% | 22.1% | 22.4% | 22.6% | 21.6% | 23.0% |
| Return on capital | 0.9% | −4.5% | 0.6% | 5.8% | 13.8% | 3.7% | 1.0% | 2.5% | 4.2% | 9.6% |
| Return on equity | −0.4% | −50.7% | −4.3% | 6.4% | 55.0% | 3.2% | 0.0% | 1.7% | 4.3% | 11.5% |
| Return on assets | −0.2% | −25.1% | −1.6% | 1.9% | 19.7% | 1.5% | 0.0% | 0.9% | 2.3% | 6.5% |
| Net debt to EBITDA | 2.4x | 2.9x | 2.5x | 2.2x | 1.3x | 1.9x | 2.2x | 1.7x | 1.2x | 0.7x |